TriStrata/Mary Kay suit
This article was originally published in The Rose Sheet
Executive Summary
Wilmington, Del. federal court denied Mary Kay's post-trial motions to set aside jury verdict in alpha hydroxy acid patent infringement case, and entered final judgment, with interest, in TriStrata's favor, NeoStrata division reports April 5. Interest on back royalties will bring total amount of the judgment to about $41.4 mil., firm notes. Mary Kay had sought to set aside a 2005 jury verdict, which found the company infringed three TriStrata patents and required direct-seller to pay $26.4 mil. TriStrata won similar AHA patent infringement cases against Valeant Pharmaceuticals, which also failed to overturn a jury verdict (1"The Rose Sheet" March 10, 2004, In Brief)...
You may also be interested in...
Tristrata lawsuit
Valeant Pharmaceutical's motion seeking to overturn a jury verdict finding the company infringed two patents held by Tristrata Corporation and requesting a new trial is rejected by Wilmington, Del. federal court, according to parent company NeoStrata. Court also issues a permanent injunction prohibiting Valeant from the "manufacture, sale and marketing of products covered by the infringed patents." In November, the court ruled that Valeant willfully infringed the two patents, which cover the use of alpha hydroxy acids "to enhance the therapeutic effect of other substances" (1"The Rose Sheet" Dec. 1, 2003, In Brief). Patent infringement suits are still pending against other firms including Mary Kay cosmetics and BeautiControl...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.